AngioDynamics Stock News

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

Like the Nasdaq Composite, this little-known medical device stock has been beaten down in 2022.

AngioDynamics posted better sales growth in FQ4'22 as elective procedure counts continue to rebound, but margin pressures continue to weigh significantly. The company is building a sustainable core gr

Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EV/sales, Raymond James believes

AngioDynamics, Inc. (NASDAQ:ANGO ) Q4 2022 Earnings Conference Call July 12, 2022 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice

AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand

AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.

AngioDynamics "beat earnings" in Q3 -- but what does that really mean?

AngioDynamics, Inc. (ANGO) CEO Jim Clemmer on Q3 2022 Results - Earnings Call Transcript

AngioDynamics Inc (NASDAQ: ANGO) has reported a Q3 FY22 adjusted EPS of $0.03, ahead of the consensus of $(0.01), and better than the consensus of $0.02 reported a year ago. Q3 sales increased 3.9%

SAN FRANCISCO , March 11, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Central Venous Catheters (CVCs) - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 7; Released: February 2022 Executive Pool: 4019 Companies: 61 - Players covered include Amecath; AngioDynamics Inc.; B. Braun Melsungen AG; Bactiguard AB; Becton, Dickinson and Company; COOK MEDICAL LLC; Edwards Lifesciences Corporation; Guangdong Baihe Medical Technology Co., Ltd; ICU Medical, Inc.; Insung Medical Co.

New York, USA, March 09, 2022 (GLOBE NEWSWIRE) -- The Global Peripherally Inserted Central Catheters (PICC) Market To Progress At A CAGR of 5.23% During The Study Period (2018-26) As per DelveInsight analysis, the Peripherally Inserted Central Catheters market size is increasing owing to the factors such as rising incidence of cancer, infectious diseases, growing demand for PICC, integration of advanced technologies to the existing products, new product launches by leading players, among others. DelveInsight''s Peripherally Inserted Central Catheters Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Peripherally Inserted Central Catheters companies in the market. Key Takeaways from the Global Peripherally Inserted Central Catheters Market According to DelveInsight analysis, North America is anticipated to dominate the global Peripherally Inserted Central Catheters market during the forecast period.